1. Neumann O, Burn TC, Allgäuer M, Ball M, Kirchner M, Albrecht T, Volckmar AL, Beck S, Endris V, Goldschmid H, Lehmann U, Seker-Cin H, Uhrig S, Roessler S, Budczies J, Fröhling S, Longerich T, Wagner AH, Vogel A, Schirmacher P, Stenzinger A, Kazdal D. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. 2022 Nov;127(8):1540-1549. doi: 10.1038/s41416-022-01908-1. Epub 2022 Jul 23. PubMed PMID: 35871236; PubMed Central PMCID: PMC9553883.
2. Wessels F, Kuntz S, Krieghoff-Henning E, Schmitt M, Braun V, Worst TS, Neuberger M, Steeg M, Gaiser T, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Artificial intelligence to predict oncological outcome directly from hematoxylin and eosin-stained slides in urology. Minerva Urol Nephrol. 2022 Oct;74(5):538-550. doi: 10.23736/S2724-6051.22.04758-9. Epub 2022 Mar 11. PubMed PMID: 35274903.
3. Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2022 Sep;84:242-254. doi: 10.1016/j.semcancer.2021.05.026. Epub 2021 May 24. Review. PubMed PMID: 34033893.
4. Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 Sep;84:1-2. doi: 10.1016/j.semcancer.2022.05.008. Epub 2022 May 18. PubMed PMID: 35597437.
5. van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 Sep;84:228-241. doi: 10.1016/j.semcancer.2022.05.011. Epub 2022 May 25. Review. PubMed PMID: 35643220.
6. Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022 Jun 25;172:107-118. doi: 10.1016/j.ejca.2022.05.025. [Epub ahead of print] PubMed PMID: 35763870.
7. Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Jun 24;50(11):e61. doi: 10.1093/nar/gkac113. PubMed PMID: 35188570.
8. Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6. PubMed PMID: 35681079.
9. Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. Virchows Arch. 2022 Jun 7;. doi: 10.1007/s00428-022-03349-w. [Epub ahead of print] PubMed PMID: 35668118.
10. Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Gieldon L, Allgäuer M, Volckmar AL, Dikow N, Renner M, Kirchner M, Penzel R, Ploeger C, Brandt R, Seker-Cin H, Budczies J, Heilig CE, Neumann O, Schaaf CP, Schirmacher P, Fröhling S, Stenzinger A. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes Cancer. 2022 Jun;61(6):303-313. doi: 10.1002/gcc.22987. Epub 2021 Aug 9. Review. PubMed PMID: 34331337.
11. Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. Mol Oncol. 2022 May 27;. doi: 10.1002/1878-0261.13256. [Epub ahead of print] PubMed PMID: 35621918.
12. van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 May 25;. doi: 10.1016/j.semcancer.2022.05.011. [Epub ahead of print] Review. PubMed PMID: 35643220.
13. Wästerlid T, Cavelier L, Haferlach C, Konopleva M, Fröhling S, Östling P, Bullinger L, Fioretos T, Smedby KE. Application of precision medicine in clinical routine in haematology-Challenges and opportunities. J Intern Med. 2022 May 22;. doi: 10.1111/joim.13508. [Epub ahead of print] Review. PubMed PMID: 35599019.
14. Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 May 18;. doi: 10.1016/j.semcancer.2022.05.008. [Epub ahead of print] PubMed PMID: 35597437.
15. Schedel A, Friedrich UA, Morcos MNF, Wagener R, Mehtonen J, Watrin T, Saitta C, Brozou T, Michler P, Walter C, Försti A, Baksi A, Menzel M, Horak P, Paramasivam N, Fazio G, Autry RJ, Fröhling S, Suttorp M, Gertzen C, Gohlke H, Bhatia S, Wadt K, Schmiegelow K, Dugas M, Richter D, Glimm H, Heinäniemi M, Jessberger R, Cazzaniga G, Borkhardt A, Hauer J, Auer F. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma. Int J Mol Sci. 2022 May 5;23(9). doi: 10.3390/ijms23095174. PubMed PMID: 35563565; PubMed Central PMCID: PMC9106003.
16. Hauser K, Kurz A, Haggenmüller S, Maron RC, von Kalle C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Kutzner H, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Hekler A, Krieghoff-Henning E, Brinker TJ. Explainable artificial intelligence in skin cancer recognition: A systematic review. Eur J Cancer. 2022 May;167:54-69. doi: 10.1016/j.ejca.2022.02.025. Epub 2022 Apr 5. Review. PubMed PMID: 35390650.
17. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 May;3(5):649. doi: 10.1038/s43018-022-00378-x. PubMed PMID: 35449310.
18. Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D. Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report. Cold Spring Harb Mol Case Stud. 2022 Apr;8(3). doi: 10.1101/mcs.a006156. Print 2022 Apr. PubMed PMID: 35058282; PubMed Central PMCID: PMC9059782.
19. Nitsch L, Jensen P, Yoon H, Koeppel J, Burman SSR, Fischer ES, Scholl C, Fröhling S, Słabicki M. BTBBCL6 dimers as building blocks for reversible drug-induced protein oligomerization. Cell Rep Methods. 2022 Apr 25;2(4):100193. doi: 10.1016/j.crmeth.2022.100193. eCollection 2022 Apr 25. PubMed PMID: 35497498; PubMed Central PMCID: PMC9046236.
20. Berthold R, Isfort I, Erkut C, Heinst L, Grünewald I, Wardelmann E, Kindler T, Åman P, Grünewald TGP, Cidre-Aranaz F, Trautmann M, Fröhling S, Scholl C, Hartmann W. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis. 2022 Apr 22;11(1):20. doi: 10.1038/s41389-022-00394-7. PubMed PMID: 35459264; PubMed Central PMCID: PMC9033823.
21. Simon M, Mughal SS, Horak P, Uhrig S, Buchloh J, Aybey B, Stenzinger A, Glimm H, Fröhling S, Brors B, Imbusch CD. Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. J Transl Med. 2022 Apr 2;20(1):152. doi: 10.1186/s12967-022-03316-8. PubMed PMID: 35366909; PubMed Central PMCID: PMC8977019.
22. Wessels F, Kuntz S, Krieghoff-Henning E, Schmitt M, Braun V, Worst TS, Neuberger M, Steeg M, Gaiser T, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Artificial intelligence to predict oncological outcome directly from hematoxylin & eosin-stained slides in urology: a systematic review. Minerva Urol Nephrol. 2022 Mar 11;. doi: 10.23736/S2724-6051.22.04758-9. [Epub ahead of print] PubMed PMID: 35274903.
23. Maurus K, Kosnopfel C, Kneitz H, Appenzeller S, Schrama D, Glutsch V, Roth S, Gerhard-Hartmann E, Rosenfeldt M, Möhrmann L, Fröhlich M, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Goebeler M, Rosenwald A, Kutzner H, Schilling B. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway. Br J Dermatol. 2022 Mar;186(3):553-563. doi: 10.1111/bjd.20869. Epub 2021 Dec 21. PubMed PMID: 34726260.
24. Brinker TJ, Schmitt M, Krieghoff-Henning EI, Barnhill R, Beltraminelli H, Braun SA, Carr R, Fernandez-Figueras MT, Ferrara G, Fraitag S, Gianotti R, Llamas-Velasco M, Müller CSL, Perasole A, Requena L, Sangueza OP, Santonja C, Starz H, Vale E, Weyers W, Hekler A, Kather JN, Fröhling S, Krahl D, Holland-Letz T, Utikal JS, Saggini A, Kutzner H. Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists. J Am Acad Dermatol. 2022 Mar;86(3):640-642. doi: 10.1016/j.jaad.2021.02.009. Epub 2021 Feb 11. PubMed PMID: 33581189.
25. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261. doi: 10.1038/s43018-022-00332-x. Epub 2022 Feb 24. PubMed PMID: 35221333; PubMed Central PMCID: PMC8882467.
26. Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Feb 21;. doi: 10.1093/nar/gkac113. [Epub ahead of print] PubMed PMID: 35188570.
27. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S. Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer. 2022 Feb;162:245-246. doi: 10.1016/j.ejca.2021.11.014. Epub 2021 Dec 22. PubMed PMID: 34953660.
28. Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14. PubMed PMID: 34125345; PubMed Central PMCID: PMC8783861.
29. Schneider L, Laiouar-Pedari S, Kuntz S, Krieghoff-Henning E, Hekler A, Kather JN, Gaiser T, Fröhling S, Brinker TJ. Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. Eur J Cancer. 2022 Jan;160:80-91. doi: 10.1016/j.ejca.2021.10.007. Epub 2021 Nov 19. PubMed PMID: 34810047.